Neil Solomons - Sep 10, 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role: Chief Medical Officer
Signature: /s/ Neil Solomons, M.D.
Stock symbol: AUPH
Transactions as of: Sep 10, 2021
Transactions value $: -$2,496,000
Form type: 4
Date filed: 9/14/2021, 05:11 PM
Previous filing: Aug 26, 2021
Next filing: Nov 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AUPH	Common Shares	Options Exercise	$480K	+150K	+109.25%	$3.20	287K	Sep 13, 2021	Direct	F1
transaction	AUPH	Common Shares	Sale	-$2.98M	-150K	-52.21%	$19.84	137K	Sep 10, 2021	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AUPH	Stock Option (right to buy)	Options Exercise	$0	-150K	-98.68%	$0.00	2K	Sep 13, 2021	Common Stock	150K	$3.20	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3	The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.77 to $19.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4	The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.